ArticleJournal for immunotherapy of cancer2022

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.

Osama E Rahma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.